Jiye Liu, PhD, on Clinical Implications of Findings on KDM6A as a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Posted: Thursday, January 5, 2023

Jiye Liu, PhD, of Dana-Farber Cancer Institute, discusses research on identifying novel regulators mediating CD38 expression and daratumumab sensitivity in multiple myeloma and the use of a genome-wide CRISPR-Cas9 screen. The study led to the validation of combination treatment with an FDA-approved EZH2 inhibitor plus daratumumab, which can overcome daratumumab resistance in preclinical multiple myeloma models.